Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Wuerstlein R et al. Breast cancer research and treatment 2019 Jun 175(2) 389-399

Main|Search|PHGKB




Last Posted: Dec 02, 2019

---

• Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
  Wuerstlein R et al. Breast cancer research and treatment 2019 Jun 175(2) 389-399
• Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention.
  Hart M Ragan et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Nov 22(11) 1231-1239
• Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
  Gage M M et al. Annals of oncology : official journal of the European Society for Medical Oncology 2018 29(5) 1280-1285
• Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
  Federici Carlo et al. BMJ open 2018 8(7) e022291
• The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.
  Smit Amelia K et al. Contemporary clinical trials 2018 70106-116
• Pre-implantation genetic screening should be used in all in vitro fertilisation cycles in women over the age of 35 years: AGAINST: Pre-implantation genetic screening should not be used in all IVF cycles in women over the age of 35 years.
  Ledger William et al. BJOG : an international journal of obstetrics and gynaecology 2019 Oct
• Preimplantation genetic screening should be used in all in vitro fertilisation cycles in women over the age of 35 years: FOR: Preimplantation genetic testing for aneuploidies should be used in all in vitro fertilisation cycles in women over the age of 35 years for optimising reproductive outcomes and minimising adverse sequelae.
  Ben Nagi Jara et al. BJOG : an international journal of obstetrics and gynaecology 2019 Oct
• Mathematics should clarify, not obfuscate: an inaccurate and misleading calculation of the cost-effectiveness of preimplantation genetic testing for aneuploidy.
  Paulson Richard J et al. Fertility and sterility 2019 111(6) 1113-1114
• 2017 Focused Update of the 2016�ACC�Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in�the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
  Lloyd-Jones Donald M et al. Journal of the American College of Cardiology 2017 Oct 70(14) 1785-1822
• 'Six million lives could be saved by 2030' through data science,
  by Gilbert Nakweya, Sci Dev Net, October 10, 2019

more